ILK-IN-3 is an orally active integrin linked kinase (ILK) inhibitor. ILK-IN-3 improves the anticancer efficacy of Docetaxel in orthotopic LCC6 model. In Vitro ILK-IN-3 (compound 4, 10 μM) inhibits DYRK1, GSK3α/β, CDK5/p25 kinase activity to 17%, 51%, 47%, 95%, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo ILK-IN-3 (QLT0267) (200 mg/kg，口服，28 天) 抑制原位 LCC6 模型中的肿瘤生长 。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid